The Oxford-Emergent Tuberculosis Consortium, a joint venture between the University of Oxford and Emergent BioSolutions, has signed a commercial license agreement with US biopharmaceutical firm Vivalis to evaluate large-scale commercial production capabilities for MVA85A, the Consortium's new tuberculosis vaccine candidate.
Under the terms of the deal, the Consortium will explore production of MVA85A using the Vivalis proprietary EB66 cell line, which is derived from duck embryonic stem cells. This cell line possesses unique industrial and regulatory characteristics such as long-term genetic stability and immortality, growth in serum-free medium and proliferation at high cell densities in suspension, the firms noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze